TABLE 4.
Possible predictors of successful eradication*
| Variable |
Treatment, n (% [95% CI])
|
P† | |
|---|---|---|---|
| Failure (n=60) | Success (n=244) | ||
| Age, years, mean ± SD | 57.7±12.9 | 61.4±13.3 | 0.0453 |
| Nonulcer dyspepsia | 21 (35.0 [22.6–47]) | 68 (27.9 [22.2–33.5]) | 0.2768 |
| Gastroesophageal reflux disease | 15 (25.0 [13.7–36.3]) | 44 (18.0 [13.2–22.9]) | 0.2215 |
| Anemia or iron deficiency | 7 (11.7 [3.3–20.0]) | 48 (19.7 [14.6–24.7]) | 0.1490 |
| Ulcer or erosion | 4 (6.7 [0.2–13.2]) | 56 (23.0 [17.6–28.3]) | 0.0045 |
| Family history of gastric cancer | 7 (11.7 [3.3–20.0]) | 15 (6.1 [3.1–9.2]) | 0.1393 |
| Uninvestigated dyspepsia | 3 (5.0 [0.0–10.7]) | 3 (1.2 [0.0–2.6]) | 0.0600 |
| Gastric cancer | 2 (3.3 [0.0–8.0]) | 3 (1.2 [0.0–2.6]) | 0.2510 |
| Other‡ | 1 (1.7 [0.0–5.0]) | 7 (2.9 [0.8–5.0]) | 0.6022 |
| University hospital office | 31 (51.7 [38.6–64.7]) | 146 (59.8 [53.6–66.0]) | 0.2503 |
| Community office | 29 (48.3 [35.3–47.6]) | 98 (40.2 [34.0–46.4]) | 0.2503 |
| Use of yogurt | 17 (34.0 [20.4–47.6]) | 42 (18.5 [13.4–23.6]) | 0.0154 |
| Seven-day treatment | 42 (70.0 [58.1–81.9]) | 103 (42.2 [36.0–48.5]) | 0.0001 |
| 14-day treatment | 18 (30.0 [18.1–41.9]) | 141 (57.8 [51.5–64.0]) | 0.0001 |
| 100% treatment taken | 59 (98.3 [95.0–100]) | 242 (99.2 [98.0–100.0]) | 0.5521 |
| Side effects | 16 (31.4 [18.2–44.6]) | 55 (24.6 [18.9–30.2]) | 0.3152 |
| Female sex | 41 (68.3 [56.2–80.5]) | 138 (56.6 [50.3–62.8]) | 0.0968 |
| Caucasian | 58 (96.7 [92.0–100]) | 214 (88.4 [84.4–92.5]) | 0.0562 |
| Black | 2 (3.3 [0.0–8.0]) | 15 (6.2 [3.1–9.3]) | 0.3887 |
| Asian | 0 (0.0 [0.0–5.1]) | 13 (5.4 [2.5–8.2]) | 0.0665 |
| Canada/USA | 18 (30.5 [18.4–42.6]) | 54 (22.5 [17.2–27.8]) | 0.1974 |
| Western Europe | 28 (47.5 [34.3–60.6]) | 129 (53.8 [47.4–60.1]) | 0.3859 |
| Eastern Europe | 3 (5.1 [0.0–10.9]) | 11 (4.6 [1.9–7.2]) | 0.0873 |
| Africa | 3 (5.1 [0.0–10.9]) | 11 (4.6 [1.9–7.2]) | 0.0873 |
| Central and South America | 3 (5.1 [0.0–10.9]) | 17 (7.1 [3.8–10.4]) | 0.5820 |
| Middle East | 3 (5.1 [0.0–10.9]) | 7 (2.9 [0.8–5.1]) | 0.4066 |
| Asia | 1 (1.7 [0.0–5.1]) | 11 (4.6 [1.9–7.2]) | 0.3112 |
Values indicated in bold are statistically significant (ie, P≤0.05).
*
Univariate analysis;
†
χ2 test for association;
‡
Other includes gastrointestinal stromal tumour, mucosa associated lymphoid tissue lymphoma, antral nodule, etc